SE0302487D0 - Novel compounds - Google Patents

Novel compounds

Info

Publication number
SE0302487D0
SE0302487D0 SE0302487A SE0302487A SE0302487D0 SE 0302487 D0 SE0302487 D0 SE 0302487D0 SE 0302487 A SE0302487 A SE 0302487A SE 0302487 A SE0302487 A SE 0302487A SE 0302487 D0 SE0302487 D0 SE 0302487D0
Authority
SE
Sweden
Prior art keywords
sup
novel compounds
compounds
racemates
tautomers
Prior art date
Application number
SE0302487A
Other languages
English (en)
Swedish (sv)
Inventor
Peter Hansen
Hans Loenn
Antonios Nikitidis
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29212489&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE0302487(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0302487A priority Critical patent/SE0302487D0/xx
Publication of SE0302487D0 publication Critical patent/SE0302487D0/xx
Priority to TW093127678A priority patent/TW200526579A/zh
Priority to UY28513A priority patent/UY28513A1/es
Priority to US10/572,640 priority patent/US20070043036A1/en
Priority to CA002538410A priority patent/CA2538410A1/en
Priority to PCT/SE2004/001336 priority patent/WO2005026124A1/en
Priority to JP2006526856A priority patent/JP2007505902A/ja
Priority to MXPA06002723A priority patent/MXPA06002723A/es
Priority to RU2006112427/04A priority patent/RU2348617C2/ru
Priority to UAA200602252A priority patent/UA84878C2/ru
Priority to AT04775439T priority patent/ATE420861T1/de
Priority to AU2004272485A priority patent/AU2004272485B2/en
Priority to BRPI0414570-4A priority patent/BRPI0414570A/pt
Priority to HK06109477.7A priority patent/HK1089167B/en
Priority to DE602004019110T priority patent/DE602004019110D1/de
Priority to CNB2004800275174A priority patent/CN100439339C/zh
Priority to EP04775439A priority patent/EP1663974B1/en
Priority to ES04775439T priority patent/ES2319300T3/es
Priority to KR1020067005458A priority patent/KR20060096995A/ko
Priority to ARP040103354A priority patent/AR046083A1/es
Priority to SA4250300A priority patent/SA04250300B1/ar
Priority to IL173986A priority patent/IL173986A0/en
Priority to CO06026211A priority patent/CO5670357A2/es
Priority to ZA200602262A priority patent/ZA200602262B/xx
Priority to IS8394A priority patent/IS8394A/is
Priority to NO20061700A priority patent/NO20061700L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • C07D213/82Amides; Imides in position 3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84Nitriles
    • C07D213/85Nitriles in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SE0302487A 2003-09-18 2003-09-18 Novel compounds SE0302487D0 (sv)

Priority Applications (26)

Application Number Priority Date Filing Date Title
SE0302487A SE0302487D0 (sv) 2003-09-18 2003-09-18 Novel compounds
TW093127678A TW200526579A (en) 2003-09-18 2004-09-13 Novel compounds
ES04775439T ES2319300T3 (es) 2003-09-18 2004-09-15 Derivados de 2-piridona como inhibidores de elastasa neutrofila y su uso.
KR1020067005458A KR20060096995A (ko) 2003-09-18 2004-09-15 중성구 엘라스타제 억제제로서의 2-피리돈 유도체 및 그의용도
AU2004272485A AU2004272485B2 (en) 2003-09-18 2004-09-15 2-pyridone derivatives as neutrophil elastase inhibitors and their use
HK06109477.7A HK1089167B (en) 2003-09-18 2004-09-15 2-pyridone derivatives as netrophil elastase inhibitors and their use
CA002538410A CA2538410A1 (en) 2003-09-18 2004-09-15 2-pyridone derivatives as netrophil elastase inhibitors and their use
PCT/SE2004/001336 WO2005026124A1 (en) 2003-09-18 2004-09-15 2-pyridone derivatives as netrophil elastase inhibitors and their use
JP2006526856A JP2007505902A (ja) 2003-09-18 2004-09-15 好中球エラスターゼ阻害剤としての2−ピリドン誘導体およびその使用
MXPA06002723A MXPA06002723A (es) 2003-09-18 2004-09-15 Derivados de 2-piridona como inhibidores de neutrofilo elastasa y su uso.
RU2006112427/04A RU2348617C2 (ru) 2003-09-18 2004-09-15 Производные 2-пиридона в качестве ингибиторов эластазы нейтрофилов и их применение
UAA200602252A UA84878C2 (ru) 2003-09-18 2004-09-15 Производные 2-пиридона как ингибиторы нейтрофилов эластазы, фармацевтическая композиция на их основе, способ их получения
AT04775439T ATE420861T1 (de) 2003-09-18 2004-09-15 2-pyridonderivate als inhibitoren von neutrophilelastase und deren verwendung
UY28513A UY28513A1 (es) 2003-09-18 2004-09-15 Nuevos compuestos
BRPI0414570-4A BRPI0414570A (pt) 2003-09-18 2004-09-15 derivados de 2-piridona como inibidores de elastase de neutrófilo e seu uso
US10/572,640 US20070043036A1 (en) 2003-09-18 2004-09-15 2-Pyridone derivatives as neutrophil elastase inhibitors and their use
DE602004019110T DE602004019110D1 (de) 2003-09-18 2004-09-15 2-pyridonderivate als inhibitoren von neutrophilelastase und deren verwendung
CNB2004800275174A CN100439339C (zh) 2003-09-18 2004-09-15 用作嗜中性白细胞弹性蛋白酶抑制剂的2-吡啶酮衍生物及其用途
EP04775439A EP1663974B1 (en) 2003-09-18 2004-09-15 2-pyridone derivatives as netrophil elastase inhibitors and their use
ARP040103354A AR046083A1 (es) 2003-09-18 2004-09-17 Derivados de 2 piridona como inhibidores de la elastasa de neutrofilos
SA4250300A SA04250300B1 (ar) 2003-09-18 2004-09-18 مشتقات 2_ بيريدون تعمل كمثبطات لانزيم ايلاستيز النتيروفيل واستخدامها
IL173986A IL173986A0 (en) 2003-09-18 2006-02-27 2-pyridone derivatives as netrophil elastase inhibitors and their use
CO06026211A CO5670357A2 (es) 2003-09-18 2006-03-15 Derivados de 2-piridona como inhibidores de elastasa neutrofila y su uso
ZA200602262A ZA200602262B (en) 2003-09-18 2006-03-17 2-Pyridone derivatives as neutrophil elastase inhibitors and their use
IS8394A IS8394A (is) 2003-09-18 2006-03-31 2-pýridónafleiður sem daukyrningselastasatálmar og notkun þeirra
NO20061700A NO20061700L (no) 2003-09-18 2006-04-18 2-pyridonderivater som neutrofil elastase inhibitorer og deres anvendelse

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0302487A SE0302487D0 (sv) 2003-09-18 2003-09-18 Novel compounds

Publications (1)

Publication Number Publication Date
SE0302487D0 true SE0302487D0 (sv) 2003-09-18

Family

ID=29212489

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0302487A SE0302487D0 (sv) 2003-09-18 2003-09-18 Novel compounds

Country Status (25)

Country Link
US (1) US20070043036A1 (en:Method)
EP (1) EP1663974B1 (en:Method)
JP (1) JP2007505902A (en:Method)
KR (1) KR20060096995A (en:Method)
CN (1) CN100439339C (en:Method)
AR (1) AR046083A1 (en:Method)
AT (1) ATE420861T1 (en:Method)
AU (1) AU2004272485B2 (en:Method)
BR (1) BRPI0414570A (en:Method)
CA (1) CA2538410A1 (en:Method)
CO (1) CO5670357A2 (en:Method)
DE (1) DE602004019110D1 (en:Method)
ES (1) ES2319300T3 (en:Method)
IL (1) IL173986A0 (en:Method)
IS (1) IS8394A (en:Method)
MX (1) MXPA06002723A (en:Method)
NO (1) NO20061700L (en:Method)
RU (1) RU2348617C2 (en:Method)
SA (1) SA04250300B1 (en:Method)
SE (1) SE0302487D0 (en:Method)
TW (1) TW200526579A (en:Method)
UA (1) UA84878C2 (en:Method)
UY (1) UY28513A1 (en:Method)
WO (1) WO2005026124A1 (en:Method)
ZA (1) ZA200602262B (en:Method)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200500341A (en) * 2002-11-12 2005-01-01 Astrazeneca Ab Novel compounds
SE0302486D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
US7432373B2 (en) 2004-06-28 2008-10-07 Bristol-Meyers Squibb Company Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
US20050288290A1 (en) 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
US7439246B2 (en) 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
TW200700392A (en) * 2005-03-16 2007-01-01 Astrazeneca Ab Novel compounds
EP1928454B1 (en) 2005-05-10 2014-09-24 Intermune, Inc. Pyridone derivatives for modulating stress-activated protein kinase system
BRPI0614290A2 (pt) 2005-08-08 2011-03-22 Argenta Discovery Ltd derivados de biciclo [ 2.2.1 ] hept-7-ilamina e seus usos
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
JP2009509979A (ja) * 2005-09-29 2009-03-12 ユニバーシティ オブ アルバータ グランザイムb阻害のための組成物および方法
GB0605469D0 (en) * 2006-03-17 2006-04-26 Argenta Discovery Ltd Multimers of heterocyclic compounds and their use
TW200808763A (en) 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds I
TW200808771A (en) * 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds II
EP2077262A4 (en) 2006-10-23 2011-12-28 Takeda Pharmaceutical IMINOPYRIDINE DERIVATIVE AND USE THEREOF
HRP20130626T1 (en) 2006-11-08 2013-08-31 Bristol-Myers Squibb Company Pyridinone compounds
KR20100096131A (ko) * 2007-11-06 2010-09-01 아스트라제네카 아베 특정 2-피라지논 유도체 및 호중구 엘라스타제의 억제제로서의 이의 용도
CA2707785C (en) 2007-12-14 2015-11-03 Pulmagen Therapeutics (Asthma) Limited Indoles and their therapeutic use
DK2235002T3 (da) 2008-01-23 2013-03-11 Bristol Myers Squibb Co 4-pyridinonforbindelser og anvendelse heraf til behandling af cancer
US8481569B2 (en) 2008-04-23 2013-07-09 Takeda Pharmaceutical Company Limited Iminopyridine derivatives and use thereof
MX2010012848A (es) 2008-06-03 2011-03-01 Intermune Inc Compuestos y metodos para tratar trastornos inflamatorios y fibroticos.
CA2752693A1 (en) 2009-02-17 2010-08-26 Chiesi Farmaceutici S.P.A. Triazolopyridine derivatives as p38 map kinase inhibitors
GB0902648D0 (en) 2009-02-17 2009-04-01 Argenta Discovery Ltd Pharmaceutical compounds and compositions
TW201036957A (en) 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
KR20120099639A (ko) * 2009-10-02 2012-09-11 아스트라제네카 아베 호중구 엘라스타제의 억제제로서 사용되는 2-피리돈 화합물
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
BR112012013582A2 (pt) * 2009-12-08 2016-07-05 Boehringer Ingelheim Int processo para síntese de intermediários úteis para a produção de compostos de indazol e azaindazol substituídos
GB201009731D0 (en) 2010-06-10 2010-07-21 Pulmagen Therapeutics Inflamma Kinase inhibitors
JP5709999B2 (ja) 2011-08-01 2015-04-30 大日本住友製薬株式会社 ウラシル誘導体およびその医薬用途
SG10201604656YA (en) 2011-12-09 2016-07-28 Chiesi Farma Spa Kinase inhibitors
KR20140103925A (ko) 2011-12-09 2014-08-27 키에시 파르마슈티시 엣스. 피. 에이. 4-히드록시-1,2,3,4-테트라히드로나프탈렌-1-일 우레아 및 호흡기 질환의 치료에서의 이들의 용도
DK2788349T3 (en) 2011-12-09 2017-01-30 Chiesi Farm Spa kinase inhibitors
US20140057926A1 (en) 2012-08-23 2014-02-27 Boehringer Ingelheim International Gmbh Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
US20140057920A1 (en) 2012-08-23 2014-02-27 Boehringer Ingelheim International Gmbh Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
US9102624B2 (en) 2012-08-23 2015-08-11 Boehringer Ingelheim International Gmbh Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
WO2014195402A1 (en) 2013-06-06 2014-12-11 Chiesi Farmaceutici S.P.A. Kinase inhibitors
US9221807B2 (en) * 2014-02-21 2015-12-29 Boehringer Ingelheim International Gmbh Substituted pyridones and pyrazinones and their use as inhibitors of neutrophil elastase activity
CN106459042B (zh) 2014-04-02 2019-06-28 英特穆恩公司 抗纤维化吡啶酮类
CN108137542B (zh) 2015-09-02 2023-10-27 葛兰素史克知识产权第二有限公司 用作溴结构域抑制剂的吡啶酮二甲酰胺
TW201720828A (zh) 2015-11-23 2017-06-16 赫孚孟拉羅股份公司 治療性化合物及組合物以及其使用方法
AR107165A1 (es) 2015-12-23 2018-03-28 Chiesi Farm Spa Inhibidores de quinasa
WO2017108736A1 (en) 2015-12-23 2017-06-29 Chiesi Farmaceutici S.P.A. N-[3-(3-{4-[[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl} -ureido)-phenyl]-methanesulfonamide derivatives and their use as p38 mapk inhibitors
AR107164A1 (es) 2015-12-23 2018-03-28 Chiesi Farm Spa INHIBIDORES DE QUINASA p38
EP3452464B1 (en) 2016-05-05 2021-12-15 F. Hoffmann-La Roche AG Pyrazole derivatives, compositions and therapeutic use thereof
SG11201901954XA (en) 2016-09-06 2019-04-29 Hoffmann La Roche 8-(azetidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridinyl compounds, compositions and methods of use thereof
CN110114343B (zh) 2016-12-29 2022-09-06 豪夫迈·罗氏有限公司 吡唑并嘧啶化合物及其使用方法
CN110494434B (zh) 2017-03-14 2022-05-24 豪夫迈·罗氏有限公司 吡唑并氯苯基化合物、其组合物及其使用方法
CA3061236A1 (en) 2017-05-22 2018-11-29 F. Hoffmann-La Roche Ag Therapeutic compounds and compositions, and methods of use thereof
JP7228318B6 (ja) 2017-05-22 2023-03-10 エフ. ホフマン-ラ ロシュ アーゲー 処置用化合物及び組成物、並びにその使用方法
US10364245B2 (en) 2017-06-07 2019-07-30 Chiesi Farmaceutici S.P.A. Kinase inhibitors
CN111587250A (zh) 2018-01-15 2020-08-25 豪夫迈·罗氏有限公司 作为jak抑制剂的吡唑并嘧啶化合物
CN111683976B (zh) 2018-02-05 2022-11-18 生物辐射实验室股份有限公司 具有阴离子交换-疏水混合模式配体的色谱树脂
CN110192947B (zh) * 2019-05-28 2022-01-04 河南省超亚医药器械有限公司 一种小儿肺部热敷贴
CN110192948B (zh) * 2019-05-28 2022-01-04 河南省超亚医药器械有限公司 一种小儿腹部热敷贴
EP3986900A1 (en) 2019-06-18 2022-04-27 F. Hoffmann-La Roche AG Tetrazole-substituted pyrazolopyrimidine inhibitors of jak kinases and uses thereof
WO2020257143A1 (en) 2019-06-18 2020-12-24 Genentech, Inc. Pyrazolopyrimidine aryl ether inhibitors of jak kinases and uses thereof
PE20220577A1 (es) 2019-06-18 2022-04-20 Hoffmann La Roche Inhibidores de jak cinasas basados en pirazolopirimidina sulfona y usos de los mismos
CN114650819A (zh) 2019-09-17 2022-06-21 美莱奥生物制药第四有限公司 用于治疗移植物排斥、闭塞性细支气管炎综合征和移植物抗宿主病的阿维来司他
PT4106757T (pt) 2020-04-16 2023-11-17 Mereo Biopharma 5 Inc Métodos que envolvem o inibidor da elastase neutrofílica alvelestat para o tratamento de doenças respiratórias mediadas pela deficiência de alfa 1 antitripsina
JP2024540952A (ja) 2021-10-20 2024-11-06 メレオ バイオファーマ 4 リミテッド 線維化の治療における使用のための好中球エラスターゼ阻害剤
CN114057630B (zh) * 2021-12-23 2023-06-02 郑州大学 吡非尼酮衍生物及其合成方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9207145D0 (en) * 1991-04-18 1992-05-13 Ici Plc Heterocyclic amides
US5521179A (en) * 1991-04-18 1996-05-28 Zeneca Limited Heterocyclic amides
FR2687674B1 (fr) * 1992-02-07 1995-05-19 Roussel Uclaf Nouveaux derives de la pyridone, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant.
RU2140917C1 (ru) * 1993-11-19 1999-11-10 Парк, Дэвис энд Компани Производные 5,6-дигидропирона и фармацевтическая композиция на их основе
RU2067579C1 (ru) * 1994-10-07 1996-10-10 Пермский фармацевтический институт 3-(2'-нафтоилметилен)-пиперазинон-2 и 1-n-фенил-3-фенацилиденпиперазинон-2, проявляющие противовоспалительную активность
ATE438624T1 (de) * 2000-12-28 2009-08-15 Shionogi & Co 2-pyridonderivate mit affinität für den cannabinoid-typ-2-rezeptor
GB0129260D0 (en) * 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
EP1458682B1 (en) * 2001-12-20 2006-08-30 Bayer HealthCare AG 1,4-dihydro-1,4-diphenylpyridine derivatives
GB2383326A (en) * 2001-12-20 2003-06-25 Bayer Ag Antiinflammatory dihydropyridines
TW200500341A (en) * 2002-11-12 2005-01-01 Astrazeneca Ab Novel compounds
SE0302486D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
DE602004019110D1 (de) 2009-03-05
ZA200602262B (en) 2007-07-25
KR20060096995A (ko) 2006-09-13
AR046083A1 (es) 2005-11-23
CN1856467A (zh) 2006-11-01
MXPA06002723A (es) 2006-06-06
IS8394A (is) 2006-03-31
EP1663974A1 (en) 2006-06-07
AU2004272485B2 (en) 2008-03-13
SA04250300B1 (ar) 2008-09-07
HK1089167A1 (en) 2006-11-24
NO20061700L (no) 2006-04-18
US20070043036A1 (en) 2007-02-22
CO5670357A2 (es) 2006-08-31
UY28513A1 (es) 2005-04-29
ES2319300T3 (es) 2009-05-06
UA84878C2 (ru) 2008-12-10
RU2348617C2 (ru) 2009-03-10
JP2007505902A (ja) 2007-03-15
RU2006112427A (ru) 2007-11-10
BRPI0414570A (pt) 2006-11-07
WO2005026124A1 (en) 2005-03-24
TW200526579A (en) 2005-08-16
CN100439339C (zh) 2008-12-03
ATE420861T1 (de) 2009-01-15
IL173986A0 (en) 2006-07-05
EP1663974B1 (en) 2009-01-14
CA2538410A1 (en) 2005-03-24
AU2004272485A1 (en) 2005-03-24

Similar Documents

Publication Publication Date Title
SE0302487D0 (sv) Novel compounds
SE0302324D0 (sv) Novel compounds
SE0302486D0 (sv) Novel compounds
SE0302323D0 (sv) Novel compounds
MY137133A (en) Novel compounds
SE0202463D0 (sv) Novel compounds
ECSP044992A (es) Inhibidores de la alquín-aril fosfodiesterasa-4
NO20075059L (no) Nye forbindelser II 2-pyridinderivater som inhibitorer av neutrofil elastase
NO20025601L (no) Arylmetylaminderivater for anvendelse som tryptaseinhibitorer
NO20044995L (no) Heterosykliske forbindelser
SE0302139D0 (sv) Novel compounds
ATE386725T1 (de) Heterocyclylverbindungen
SE0203304D0 (sv) Novel Coumpounds
SE0302756D0 (sv) Novel Compounds
SE0303280D0 (sv) Novel compounds
SE9803773D0 (sv) Compounds
SE0202461D0 (sv) Novel compounds
DE60103034D1 (de) Neue phenylheteroalkylamin-derivate
SE0403118D0 (sv) New compounds 2
SE9904676D0 (sv) Novel compounds
SE9901901D0 (sv) Compounds
SE0102640D0 (sv) Novel compounds
SE0103325D0 (sv) Novel compounds
NO20042729L (no) Heksasykliske forbindelser
SE0403117D0 (sv) New compounds 1